PE20151435A1 - Laquinimod para reducir el dano talamico en la esclerosis multiple - Google Patents

Laquinimod para reducir el dano talamico en la esclerosis multiple

Info

Publication number
PE20151435A1
PE20151435A1 PE2015000472A PE2015000472A PE20151435A1 PE 20151435 A1 PE20151435 A1 PE 20151435A1 PE 2015000472 A PE2015000472 A PE 2015000472A PE 2015000472 A PE2015000472 A PE 2015000472A PE 20151435 A1 PE20151435 A1 PE 20151435A1
Authority
PE
Peru
Prior art keywords
laquinimod
multiple sclerosis
thalamic damage
reduce
damage
Prior art date
Application number
PE2015000472A
Other languages
English (en)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20151435A1 publication Critical patent/PE20151435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)

Abstract

La invencion proporciona metodos para inhibir o reducir el dano talamico en un sujeto, que comprende administrar laquinimod a un sujeto afectado con esclerosis multiple
PE2015000472A 2012-10-12 2013-10-09 Laquinimod para reducir el dano talamico en la esclerosis multiple PE20151435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
PE20151435A1 true PE20151435A1 (es) 2015-10-15

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000472A PE20151435A1 (es) 2012-10-12 2013-10-09 Laquinimod para reducir el dano talamico en la esclerosis multiple

Country Status (18)

Country Link
US (2) US20140107154A1 (es)
EP (1) EP2961406A4 (es)
JP (1) JP2015533163A (es)
KR (1) KR20150080509A (es)
CN (1) CN105263325A (es)
AR (1) AR092993A1 (es)
AU (2) AU2013329348A1 (es)
BR (1) BR112015007782A2 (es)
CA (1) CA2884272A1 (es)
CL (2) CL2015000732A1 (es)
EA (1) EA201590726A1 (es)
HK (1) HK1218865A1 (es)
IL (1) IL237745A0 (es)
MX (1) MX2015004564A (es)
PE (1) PE20151435A1 (es)
SG (1) SG11201501874TA (es)
TW (1) TW201420101A (es)
WO (1) WO2014058979A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009373A (es) 2012-02-03 2014-08-27 Teva Pharma Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea.
CA2863409A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
MX2016008027A (es) * 2013-12-20 2016-10-12 Teva Pharma Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
JP2017514824A (ja) 2014-04-29 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
BR112019004791A2 (pt) * 2016-09-13 2019-06-04 Intekrin Therapeutics Inc tratamento de esclerose múltipla com chs-131
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2008009407A2 (en) * 2006-07-17 2008-01-24 Novartis Ag Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
PL2442651T3 (pl) * 2009-06-19 2015-12-31 Teva Pharma Leczenie stwardnienia rozsianego za pomocą lakwinimodu
EP2467372B1 (en) * 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
UA111959C2 (uk) * 2010-12-07 2016-07-11 Тева Фармасьютікл Індастріз Лтд. Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом
EP2691393B1 (en) * 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
BR112014008731A2 (pt) * 2011-10-12 2017-04-25 Teva Pharma tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途

Also Published As

Publication number Publication date
WO2014058979A3 (en) 2015-08-20
WO2014058979A2 (en) 2014-04-17
US20160296511A1 (en) 2016-10-13
CL2015000732A1 (es) 2015-08-07
CA2884272A1 (en) 2014-04-17
HK1218865A1 (zh) 2017-03-17
AU2017203896A1 (en) 2017-06-29
AR092993A1 (es) 2015-05-13
US20140107154A1 (en) 2014-04-17
CN105263325A8 (zh) 2017-07-14
IL237745A0 (en) 2015-05-31
MX2015004564A (es) 2015-07-21
JP2015533163A (ja) 2015-11-19
EA201590726A1 (ru) 2015-10-30
SG11201501874TA (en) 2015-05-28
WO2014058979A8 (en) 2015-04-16
BR112015007782A2 (pt) 2017-07-04
CL2016002873A1 (es) 2017-04-17
KR20150080509A (ko) 2015-07-09
CN105263325A (zh) 2016-01-20
EP2961406A2 (en) 2016-01-06
TW201420101A (zh) 2014-06-01
EP2961406A4 (en) 2017-01-04
AU2013329348A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
UY4230Q (es) Bocadillo retorcido para mascota
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2014003534A1 (es) Metodo para reducir el riesgo de un evento cardiovascular en un sujeto en terapia con estatina.
UY4211Q (es) Pizarra para marcadores
CR20110398S (es) Colchón
UY34280A (es) Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa.
UY34537A (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
MX355461B (es) Una formulacion estabilizada de pemetrexed.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
ECSP14033284A (es) Composición herbicida que tiene actividad herbicida mejorada
MX2014015039A (es) Inhibidores de fbx03.
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
UY34038A (es) Esteres aromaticos para composiciones agroquimicas.
MY175703A (en) Tablets with improved acceptance and good storage stability
BR112014032501A2 (pt) composto, e, composição farmacêutica.
ES2571402T3 (es) Producto mejorado para el cuidado de heridas
UY4241Q (es) Mesa
UY34755A (es) Agentes para el control de la glycaspis brimblecombei
UY34035A (es) Compuestos fungicidas relacionados con el 4,5-dihidroisoxazol.
CL2014002485A1 (es) Composición que comprende lactoferrina para prevenir, mejorar o tratar la diarrea.
CR20130615S (es) Contenedor
UY4189Q (es) Exhibidor para mostrador
UY4225Q (es) Casquillo pentagonal para eslingas

Legal Events

Date Code Title Description
FD Application declared void or lapsed